"so no one understands this disease and claiming that NTRP drug is inferior to AVXL is unproven"
Well said! I am an ex AVXL investor. I like NTRP's chances a lot better. Management has signaled that bryostatin will succeed in the ongoing Alzheimer's trial. They are considering expanding its use in Fragile X and other indications. The low os and float will propel the stock up on any positive news while AVXL is still stuck in the mud. I see no hope for AVXL shareholders
Market Data 
Markets 
AI
